Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29807940 | 0.98 | TAAR1 (0.55) | TAAR1GPR84HRH3GPR52DAO | |
| SCHEMBL29013833 | 0.98 | TAAR1 (0.55) | TAAR1GPR84HRH3GPR52DAO | |
| SCHEMBL6083781 | 0.89 | TAAR1 (0.53) | TAAR1GPR84HRH3GPR52DAO | |
| SCHEMBL19903876 | 0.88 | TAAR1 (0.44) | TAAR1GPR84HRH3GPR52DAO | |
| SCHEMBL1299860 | 0.87 | TAAR1 (0.52) | TAAR1GPR84HRH3DAOIDO1 | |
| SCHEMBL19258592 | 0.85 | MEN1 (0.43) | TAAR1GPR52MAOAMAOB | |
| SCHEMBL1985498 | 0.82 | TAAR1 (0.59) | TAAR1GPR84HRH3GPR52DAO | |
| SCHEMBL1124900 | 0.81 | TAAR1 (0.52) | TAAR1GPR84HRH3DAOIDO1 | |
| SCHEMBL13680790 | 0.80 | FFAR1 (0.45) | TAAR1GPR84GPR52 | |
| SCHEMBL29596752 | 0.80 | TAAR1 (0.74) | TAAR1GPR84HRH3DAOIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466790-B | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| CN-117466790-A | Preparation method of alpha-sulfinylated carbonyl compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| EP-3838901-B1 | COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES | IRIMAJIRI THERAPEUTICS INC (JP) | 2023-09-27 | — | — | EP | disclosed |
| EP-3177601-B1 | TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS | SCRIPPS RESEARCH INST (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4104902-A1 | COMPOUND AND DRUG CONTAINING SAME | Oita University Institute of Advanced Medicine, Inc. (JP) | 2022-12-21 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-115052661-A | Compound and drug using the same | 株式会社大分大学先端医学研究所 | 2022-09-13 | — | — | CN | disclosed |
| US-11292794-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same | OITA UNIVERSITY INSTITUTE OF ADVANCED MEDICINE, INC. (JP) | 2022-04-05 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| WO-2005044266-A1 | ALKYNES I | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044266-A1 | ALKYNES I | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
| EP-1201235-A1 | NEUROPATHY IMPROVERS CONTAINING NITROGENOUS COMPOUNDS AS THE ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292794-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same | AVPR1B, F12, SDHB | TAAR1 3301/4885GPR84 4720/4885HRH3 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.